Tanezumab: FDA hold

Pfizer suspended the chronic low back pain and painful DPN programs for tanezumab after FDA placed the Phase II programs on clinical hold. Last month, FDA placed a clinical hold on the osteoarthritis (OA) program due to reports of worsening OA leading to joint replacement in tanezumab-treated patients (see BioCentury, June 28). Pfizer said it has submitted additional information to FDA on the implications of these events in other tanezumab indications. ...